Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Agitated or aggressive behaviours in dementia patients, measured on the Cohen‐Mansfield Agitation Inventory (CMAI) Scale (range 29 to 203, with 29 meaning no symptoms, and higher number of points indicating more severe symptoms)Â · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
1 finding from 1 review
Intervention not reported
One or more serious adverse events · cognitively healthy people in midlife
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · people with dementia
1 finding from 1 review
Neuropsychiatric symptoms · people with dementia
1 finding from 1 review
Social functioning measured using MOSES, Withdrawn Behaviour subscale (8‐ 32, higher score indicates more severe withdrawn behaviour) · people with dementia
1 finding from 1 review
Behaviour · people with dementia
1 finding from 1 review
Agitation and irritability · people with dementia
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
FuFangHaiShe showed no clear difference in adverse events (AEs) (1 or more) compared with 'no treatment' (low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AEs) (1 or more events) · People with vascular dementia
YinDanXingNaoTong showed no clear difference in adverse events (AEs) (1 or more events) compared with 'no treatment' (low certainty).
1 finding from 1 review
AE (1 or more events) · People with vascular dementia
It is very uncertain whether fuFangHaiShe changes AE (1 or more events) compared with western medicine (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
It is very uncertain whether naoMaiTai changes adverse events (AEs) (1 or more events) compared with western medicine (very low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
NaoXinTong showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
FuFangDanShen showed no clear difference in adverse events (AEs) (1 or more) compared with 'no treatment' (low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (AEs) (1 or more events) · People with vascular dementia
ShenFuTang showed no clear difference in adverse events (AEs) (1 or more events) compared with western medicine (low certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · People with vascular dementia
TongXingLuo showed no clear difference in adverse events (AEs) (1 or more) compared with western medicine (low certainty).
1 finding from 1 review
Intervention not reported
Global cognitive function measured at the end of the intervention period (12 weeks) · cognitively healthy people in late life
1 finding from 1 review